复发非肌层浸润性膀胱癌吉西他滨膀胱内灌注治疗疗效分析  

Curative effect analysis of intravesical irrigation with gemcitabine for non-muscle-invasive bladder cancer after TURBT

作　　者：梁嘉前[1] 杨伟[1] 黄遂斌[1] 刘双林[1] 袁敬东[1] 吴维[1] 周高峰[1] 向威[1] 章传华[1] 

机构地区：[1]武汉市第一医院泌尿外科,430022

出　　处：《现代泌尿生殖肿瘤杂志》2017年第5期272-274,共3页Journal of Contemporary Urologic and Reproductive Oncology

基　　金：国家自然科学基金(81502224)

摘　　要：目的评估吉西他滨膀胱内灌注治疗复发非肌层浸润性膀胱癌的有效性及安全性。方法 54例复发非肌层浸润性膀胱癌患者均再行经尿道膀胱肿瘤切除术,术后给予吉西他滨膀胱内灌注治疗,观察患者的无瘤生存率及不良反应。结果 54例患者1年无瘤生存率为63%,其中男性1年无瘤生存率为64%,女性1年无瘤生存率为60%。54例患者中2例因频繁发作尿路刺激症状及肉眼血尿而停止灌注治疗,1例患者因灌注后发作附睾炎而停止灌注治疗,无严重不良反应发生,总不良反应发生率约为18.5%。结论吉西他滨对复发性非肌层浸润性膀胱癌治疗有效,不良反应少,可作为复发性膀胱癌患者的灌注治疗药物。Objective To assess the curative effect and drug safety of intravesical irrigation with gemcitabine for recurrent non-muscle-invasive bladder cancer（NMIBC）after being treated with TURBT＋intravesical irrigation with hydroxycamptothecine. Methods Fifty-four patients of recurrent NMIBC were treated with TURBT again,then underwent intravesical irrigation with gemcitabine.Disease free survival and side effects were observed. Results Of 54 patients treated with TURBT and intravesical irrigation with gemcitabine,one-year disease-free survival was 63%,64% for male and 60% for female patients,respectively.Two patients discontinued intravesical irrigation with gemcitabine due to frequent urinary irritation and gross hematuria.Another one patient discontinued the treatment due to epididymitis.There were no serious side effects and total side effects rate was about 18.5%. Conclusions Intravesical irrigation with gemcitabine for recurrent NMIBC is effective,and serious side effects are rare.Thus,gemcitabine can be used in intravesical irrigation for patients with recurrent bladder cancer.

关 键 词：吉西他滨 膀胱肿瘤 经尿道膀胱肿瘤切除 膀胱灌注 

分 类 号：R737.14[医药卫生—肿瘤]